吡咯烷二硫代甲酸铵
吡咯烷二硫代甲酸铵 性质
| 熔点 | 153-155 °C(lit.) |
|---|---|
| 密度 | 1.117 (estimate) |
| 折射率 | 1.5300 (estimate) |
| 储存条件 | Store at +2°C to +8°C. |
| 溶解度 | 190g/l |
| 形态 | 粉末/固体 |
| 颜色 | 白色至类白色 |
| PH值 | 6-7 (50g/l, H2O, 20℃) |
| 水溶解性 | 50 g/L (20 ºC) |
| 敏感性 | Hygroscopic |
| BRN | 3730472 |
| 稳定性 | 稳定的。与强氧化剂不相容。 |
| CAS 数据库 | 5108-96-3(CAS DataBase Reference) |
| EPA化学物质信息 | 1-Pyrrolidinecarbodithioic acid, ammonium salt (5108-96-3) |
吡咯烷二硫代甲酸铵 用途与合成方法
| Target | Value |
|
NF-κB
() |
Pretreatment of cells with Pyrrolidinedithiocarbamate ammonium (Ammonium pyrrolidinedithiocarbamate; 3-1000 μM) dose-dependently attenuate IL-8 production.
Furthermore, pyrrolidinedithiocarbamate ammonium (100 μM) suppresses the accumulation of IL-8 mRNA.
Pyrrolidinedithiocarbamate ammonium inhibits the activation of NF-κB, because it suppresses both NF-κB DNA binding and NF-κB-dependent transcriptional activity. NF-κB inhibition with pyrrolidinedithiocarbamate ammonium decrease IL-8 production by intestinal epithelial cells.
The DSS+pyrrolidinedithiocarbamate ammonium-treated groupII exhibits suppression of shortening of intestinal length and reduction of DAI score. Activated NF-κB level and IL-1β and TNF-α levels are significantly lower in DSS+pyrrolidinedithiocarbamate ammonium-treated groupII. These findings suggest that suppression of NF-κB activity by pyrrolidinedithiocarbamate ammonium can delay the healing of mucosal tissue defects (erosions or ulcers) arising from inflammation, but that it can strongly suppress the expression of inf-lammatory cytokines (IL-1β and TNF-α), resulting in significant alleviation of colitis. pyrrolidinedithiocarbamate ammonium is useful for the treatment of ulcerative colitis.
MSDS信息
吡咯烷二硫代甲酸铵 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | B23731 | 1-吡咯烷羰基二硫酸铵盐, 98% | 5108-96-3 | 25g | 669 |
| 2024-04-30 | B23731 | 1-吡咯烷羰基二硫酸铵盐, 98% | 5108-96-3 | 100g | 1588 |
